Pediatrics TeamWor 437 Common Pediatric Rheumatic Diseases

Done by:

5.0

Elham Alami Ghadah Alqarni

Revised by:

Aseel Badukhon

leam Leader

Aseel Badukhon

Notes

Book



Kawasaki disease topic includes also dr. Mohammed alghamdi slides and notes from acquired heart disease lecture to avoid repeating topics!

Approach to Arthritis



Arthritis(how to know the joint is inflamed): swelling within a joint, or limitation in the range of joint movement with joint pain or tenderness, which persists for at least 6 weeks, is observed by a physician, and is not due to primarily mechanical disorders or other identifiable causes.

Differential diagnosis of arthritis:





A nice article about Fever evaluation in pediatrics: https://www.aafp.org/afp/2013/0215/afp20130215p254.pdf

Juvenile Idiopathic Arthritis



Pathophysiology:

- → The pathogenesis of JIA is not understood well
- → Substantial evidence suggests that JIA is an autoimmune process.
- Can be triggered by infections or environmental factors
- → They usually have other Autoimmune diseases or family history of the disease

Classification:

International League of Associations for Rheumatology (ILAR)

- 1- Oligoarticular JIA.
- 2- Polyarticular rheumatoid factor positive JIA.
- 3- Polyarticular rheumatoid factor negative JIA.
- 4- Systemic JIA.
- 5- Psoriatic JIA.
- 6- Enthesitis related arthritis(ERA).
- 7- Undifferentiated.

Oligoarticular (few) JIA:

- <5 joints during the first 6 months of disease. Large joint : ankle or knees
- At high risk for developing uveitis especially ANA-positive girls "<7yrs at the onset of illness"
- Persistent & extended oligoarticular JIA.



Juvenile Idiopathic Arthritis



Oligoarticular (few) JIA:

• Every single child with oligo JIA should do eye examination. We don't expect them to have symptoms, they may present with asymptomatic uveitis (**anterior uveitis**)





This is permanent change called synechia

Irregular pupil due to the eye inflammation "uveitis". High risk: female & ANA +ve Need to be evaluated by ophtha every 10 months

Polyarticular JIA:

- RF-negative disease (20% to 30% of JIA patients)
- RF-positive disease (5% to 10% of JIA patients).
- Both types affect girls more frequently than boys.
- RF-negative patients often develop polyarthritis in early childhood
- RF-positive disease is like RA in adults "erosion and destruction of joints". The child may cotinue to have Sx even as an adult

Systemic onset juvenile idiopathic arthritis:

- Undergo extensive investigations to role out other ddx like: infection or cancer like leukemia , some may need bone marrow aspiration to r/o malignancies. They may present like leukemia!
- No specific age and gender.
- At onset, extra-articular manifestations including rash, fever, lymphadenopathy, hepatosplenomegaly, and serositis predominate.





Quotidian fever, skin rash, and arthritis this is in favor of systemic JIA

From a paper. In patients with non-typical JIA and monoarthritis accompanying with intense night pain, highly elevated acute phase reactants, and bone edema in MRI, we believe that bone marrow aspiration should be performed before treatment even if ANA positivity is present.



Enthesitis-related arthritis:

- It is the inflammation of the insertion site of a tendon ,ligament, fascia into bone
- Most common in boys older than 8 years of age.
- It has a strong genetic predisposition.
- The hallmarks of the disease are:

Stiffness

And eventual loss of mobility of the back

- Like spondyloarthropathy in adults sacroiliac joint involvement, may end up w/ bamboo sign
- Some may present w/ pain in ASIS (anterior superior iliac spine) or below the knee.
- They may have acute eye inflammation not chronic like oligoarticular JIA
- They have genetic predisposition: **HLA-B27** positivity
- Strong family history of inflammatory back pain





Bamboo sign!

Psoriatic arthritis:

- Psoriasis + arthritis , but kids may not present w/ typical features of psoriatic arthritis
- A peak age of onset in mid childhood
- Extra-articular manifestations include: rash, nail changes (including pitting, onycholysis) and uveitis.+ family history of psoriasis



Juvenile Idiopathic Arthritis



Investigations:

Dx is mainly clinical

Laboratory	Radiology
- No specific lab. can confirm the diagnosis - Lab. can be used to:	Plain x-ray
 Provide evidence of inflammation. Support the clinical diagnosis. Monitor treatment toxicity. Monitor liver enzymes and CBC Limited joint disease: Mild anemia. Moderate –extensive arthritis: Normocystic hypochromic anemia or severe anemia. Iron deficiency anemia. High WBC count. High platelets. 	 Early radiological changes: Periosteal soft tissue swelling Widening of the joint space Juxta articular osteoporosis Usually normal X-ray in initial presentation
 ESR (erythrocyte sedimentation rate): Useful but not totally reliable measure of active disease. Oligoarticular particularly may be normal Helpful in monitoring the therapeutic efficacy of the medications. CRP (c -reactive protein): More reliable monitor of inflammation response. Rheumatoid factor: help in differentiating RF +ve from -ve IgM anti IgG. RF positive in: Subcutaneous nodules. Articular erosions. ANA (antinuclear antibody): More frequent in young girls with oligo JIA Less frequent in older boys with systemic arthritis. 	Later changes:

 Final State State



In **oligo JIA** you might have completely normal labs In **systemic JIA** (high WBC , low Hgb, High plts initially but when **MAS developes (pancytopenia)**

Juvenile Idiopathic Arthritis





Systemic Lupus Erythematosus

- SLE is a multisystem autoimmune disease with a great variability in disease presentation and course. Same as adult, but more complication due to the duration of disease and medication S/E
- The diagnosis of SLE is based on the clinical and laboratory features consistent with this illness.
- The etiology of systemic lupus erythematosus (SLE) remains unknown and it is **multifactorial:**

Genetics factors	Hormonal factors	Immune abnormalities	Environmental factors
There is a high concordance rate (14 to 57 percent) of SLE in monozygotic twins. Children of mothers with lupus may have a positive test for antinuclear antibodies	More in females (4:1) The use of estrogen-containing contraceptive agents is associated with a 50 percent increase in risk of developing SLE	SLE is primarily a disease with abnormalities in immune regulation. Immune deficiency is risk factor	Viruses Ultraviolet (UV) light should avoid exposure Allergies to medications anti-TB (isoniazid), anti-HTN (hydralazine)



SLICC (Systemic Lupus International Collaborating Clinics) Classification Criteria for Systemic Lupus Erythematosus requirements:

- \rightarrow \geq 4 criteria (at least 1 clinical and 1 laboratory criteria)
- → OR biopsy-proven lupus nephritis with positive ANA or Anti-DNA

Clinical Criteria	Immunological Criteria
1.Acute Cutaneous Lupus: malar rash. Sparing nasolabial folds	
2.Subacute cutaneous lupus	
3.Chronic Cutaneous Lupus: discoid rash.	1.ANA level above laboratory reference
4.Oral Ulcers (painless) OR Nasal Ulcers.	range. Has to be +ve for Dx of SLE
5.Non-scarring alopecia. Ask about hair loss - can be early presentation of SLE	2.Anti-dsDNA antibody level above
6.Arthritis involving 2 or more joints (non-erosive)	laboratory reference range. specific, renal
7.Serositis (major): pleural effusions, pericardial effusion, and pericarditis by	involvement
electrocardiography in the absence of other causes, such as infection, uremia.	3.Anti-Smith. Also specific
Peritonitis (abdominal pain)	4.Antiphospholipid antibody. They are
8.Renal: urine protein-to-creatinine ratio (or 24-hour urine protein)	prone to secondary (APS) . ask for
representing 500 mg protein/24 hours OR red blood cell casts. Imp poor	anticardiolipin, beta-2 glycoprotein I
prognostic factor. Even with mild renal involvement sometimes we need	(β 2GPI), and lupus anticoagulant. Don't
renal bx ; why? We expect worse finding in the biopsy compared to the renal	bother yourself about names just have an
symptoms.	idea
9.Neurologic: seizures, psychosis, mononeuritis multiplex (in the absence of	5.Low complement (C3, C4, or CH50). If
other known causes), myelitis, peripheral or cranial neuropathy (in the absence	low indicates flare-up. Renal involvement
of other known causes) and acute confusional state (in the absence of other	(low C3)
causes). Ask about school performance, renal and CNS involvement affect prognosis	6.Direct Coombs' test (in the absence of
10.Hemolytic anemia (sudden drop of Hb, jaundice and dark urine)	hemolytic anemia)
11.Leukopenia (<4000/mm3) OR Lymphopenia (<1000/mm3).	
12.Thrombocytopenia (<100,000/mm3) at least once in the absence of other	Antihistone Ab \rightarrow drug- induced lupus
known causes. Pt $\ensuremath{w}\xspace$ isolated thrombocytopenia should be followed-up as they	
may develop lupus in the future.	

Systemic Lupus Erythematosus

Criteria:

TOld Criteria



Malar rash

Subacute Cutaneous Lupus



Discoid rash



Oral ulcer



Non-scarring alopecia



Antinuclear antibodies (ANA) at a titer of $\geq 1:80$ on HED-2 cells or an equivalent positive test (ever)			
lf absent	, do not cla	assify as SLE	
If present	, apply add	litive criteria	
Α	dditive crit	teria	
Do not count a criterion if th	ere is a mo	pre likely explanation than SLE.	
Occurrence of a criterion	on at leas	t one occasion is sufficient.	
SLE classification requires at	least one o	linical criterion and ≥10 points.	
Criteria need	not occur	simultaneously.	
Within each domain, only the highest w	eighted cr	iterion is counted toward the total so	core§.
Clinical domains and criteria	Weight	Immunology domains and criteria	Weight
Constitutional		Antiphospholipid antibodies	
Fever	2	Anti-cardiolipin antibodies OR	
Hematologic		Anti-β2GP1 antibodies OR	
Leukopenia	3	Lupus anticoagulant	2
Thrombocytopenia	4	Complement proteins	
Autoimmune hemolysis	4	Low C3 OR low C4	3
Neuropsychiatric		Low C3 AND low C4	4
Delirium	2	SLE-specific antibodies	
Psychosis	3	Anti-dsDNA antibody* OR	
Seizure	5	Anti-Smith antibody	6
Mucocutaneous			
Non-scarring alopecia	2		
Oral ulcers	2		
Subacute cutaneous OR discoid lupus	4		
Acute cutaneous lupus	6		
Serosal			
Pleural or pericardial effusion	5		
Acute pericarditis	6		
Musculoskeletal			
Joint involvement	6		
Renal			
Proteinuria >0.5g/24h	4		
Renal biopsy Class II or V lupus nephritis	8		
Renal biopsy Class III or IV lupus nephritis	10		
		I	
	Total sco	re:	
Classify as Systemic Lupus Erythematosus with a score of 10 or more if entry criterion fulfilled			
,			

It must reach \geq 10 points

Rules:

-1 from each category

- If you have 2 from the same category , pick the highest weight

<u>- Last one in renal = 10 If</u> present alone w/ +ve ANA we can diagnose the pt w/ SLE

It's a must to have ANA

Don't remember all the numbers but I want you to have an idea

Systemic Lupus Erythematosus

Lupus Nephritis (Notes):

Classification category	Features
Class I: minimal mesangial	Normal/minimal proteinuria, normal creatinine Earliest and mildest form of glomerular involvement
Class II: mesangial proliferative	Microscopic haematuria +/- proteinuria Hypertension uncommon and nephrotic syndrome plus renal insufficiency rarely seen
Class III: focal lupus nephritis	Haematuria, proteinuria, hypertension, reduced eGFR +/- nephrotic syndrome
Class IV: diffuse lupus nephritis	Most common and severe form of lupus nephritis Clinical features as for class III but also significantly low C3 and high dsDNA, especially in active disease
Class V: membranous nephropathy	Nephrotic syndrome, microscopic haematuria, hypertension, normal/high creatinine Can present without other clinical or serological manifestations of SLE but electron microscopy features will distinguish it from the idiopathic form
Class VI: advanced sclerosing lupus	Slowly progressive renal failure with proteinuria and bland urine sediment

Adapted from Bomback AS, Appel GB. UpToDate: 2018.12

Abbreviations: dsDNA = double-stranded DNA; eGFR = estimated glomerular filtration rate; SLE = systemic lupus erythematosus.

Lupus nephritis

- It has 6 classes
- Class 3,4 significant renal involvement (should go for aggressive Tx like cyclophosphamide,MMF or rituximab)
- Class 5 membranous nephritis (proteinuria)
- Class 6 sclerosed kidney (should go for **dialysis**)

Treatment :



General

Team approach:

- □ Counseling
- \circ \Box Education
- Appropriate nutrition
- Use of sun protection
- □ Immunization
- Prompt management of infection

Nonsteroidal Anti-inflammatory

Hydroxychloroquine Specially in skin and hematology problems

Glucocorticoids The Main treatment specially in the beginning IV in cns, renal and active

Immunosuppressives In bad cns or renal

"Red riding hood will help you to remember SLE. Lupus means wolf and erythematosus means red, and in the story the villain is the wolf and the prey is the little girl wearing red hood. SLE = commonly affects woman!"



- HSP is the most common pediatric vasculitis. Involves small arteries
- Classically presents with the triad of:



Differential diagnoses of Vasculitis (according to vessel size):



Pathophysiology:

Immunoglobulin <u>A (IgA)</u> immune complexes deposition. This is what you expect to see in skin biopsy

The major cause of morbidity is renal involvement.

3-15 years.if no renal involvement = benign disease

A wide variety of infections may trigger HSP. It's not a must but it could happen

- Skin involvement (100%) in HSP may begin as urticaria, but in most cases it progresses to dramatic purple, non-blanching lesions . Mainly lower limb vasculitis.
- Gastrointestinal involvement (75%) ranges from colicky abdominal pain to profuse bleeding, intussusception.
- The arthritis of HSP (50%) is usually transient, and it does not cause chronic joint changes.
- Renal Disease: the most serious sequelae of Henoch- Schonlein purpura is renal involvement. This
 complication occurs in about 25 percent of children





Diagnosis:

Based on the criteria

Purpura (mandatory criterion):



Treatment:

- Therapy of HSP is primarily supportive, aiming for symptomatic relief of arthritis and abdominal pain.
- Use of steroids in children who do not respond to NSAIDs (we usually don't start w/ it b.c of GI upset and renal problems used if needed) or in those thought to be at highest risk of developing renal compromise continues to be controversial.
- Indications for steroids from the beginning :

1- renal involvement 2- CNS involvement 3- sever GI bleeding





Idiopathic inflammatory myopathies (IIMs), collectively known as myositis, are heterogeneous disorders characterized by muscle weakness and muscle inflammation.

The most common subgroups in children, juvenile DM (JDM).

Incidence:

- In population-based studies, JDM has a reported annual incidence that ranges from two to four cases per one million children. Not common
- The peak incidence is from 5 to 10 years of age.

Etiology & Pathogenesis:

- Cause unknown.
- Likely autoimmune angiopathy.
- Environmental and genetic factors implicated.
 - A history of infection prior to onset is common, 65-70% of patients have a history of a significant infection during the three months prior to first onset of symptoms.
 - Proposed triggers include various infectious agents, vaccines, medications, UV light.
- Cellular and humoral immunity implicated.
- Complement-mediated injury important.
- Innate immune response: type l interferons and dendritic cells.

Dermatomyositis (other organ involvement):

- 1. Gastrointestinal vasculitis: gut wall perforation.
- 2. Arthritis: common but usually early and mild, non-erosive.
- 3. Cardiac: inflammation, fibrosis, conduction defects.
- 4. Renal: glomerular hypercellularity.
- 5. Pulmonary: fibrosis, pneumothorax. sometimes due to the weakness they might face respiratory problems and need ICU and ventilation .Rash + lung involvement (ILD) \rightarrow anti-MDA5
- 6. Central nervous system: behavior changes, seizures.
- 7. Alopecia.
- 8. Eyes: exudative vasculitis of retina.
- 9. Derm: calcinosis, subcutaneous nodules, ulcerations.
- 10. Lipodystrophy. One of the major involvement -> loss of subcutaneous fat

Differential Diagnosis:

Don't remember the details but I want to tell you that muscle weakness can present in other disease not only JDM

trophies, dystrophinopathies, facioscapulohumeral dystrophy, other dystrophies noses (glycogen-storage diseases), lipid-storage disorders, mitochondrial myopathies n, hyperthyroidism, Cushing's syndrome or exogenous steroid myopathy, diabetes mellitus tients taking any of the following drugs or biological treatments: statins, interferon α, , hydroxychloroquine, diuretics, amphotericin b, caine anaesthetics, growth hormone, cimetidine,
trophies, dystrophinopathies, facioscapulohumeral dystrophy, other dystrophies noses (glycogen-storage diseases), lipid-storage disorders, mitochondrial myopathies n, hyperthyroidism, Cushing's syndrome or exogenous steroid myopathy, diabetes mellitus tients taking any of the following drugs or biological treatments: statins, interferon α, , hydroxychloroquine, diuretics, amphotericin b, caine anaesthetics, growth hormone, cimetidine,
noses (glycogen-storage diseases), lipid-storage disorders, mitochondrial myopathies n, hyperthyroidism, Cushing's syndrome or exogenous steroid myopathy, diabetes mellitus tients taking any of the following drugs or biological treatments: statins, interferon α, , hydroxychloroquine, diuretics, amphotericin b, caine anaesthetics, growth hormone, cimetidine,
n, hyperthyroidism, Cushing's syndrome or exogenous steroid myopathy, diabetes mellitus tients taking any of the following drugs or biological treatments: statins, interferon α, , hydroxychloroquine, diuretics, amphotericin b, caine anaesthetics, growth hormone, cimetidine,
tients taking any of the following drugs or biological treatments: statins, interferon α , , hydroxychloroquine, diuretics, amphotericin b, caine anaesthetics, growth hormone, cimetidine,
vis
ratrophy
luenza, coxsackievirus, echovirus, parvovirus, poliovirus, hepatitis B, human T-lymphotropic virus 1
, streptococcus, toxoplasmosis, trichinosis, Lyme borreliosis
erythematosus, scleroderma, juvenile idiopathic arthritis, mixed connective-tissue disease, Jlitis
owel disease, coellac disease
owel disease, coeliac disease na, allergy
b

Bonanza and Peter diagnostic criteria: Old criteria but the popular

A	Proximal and symmetrical muscle weakness of the pelvic and scapular girdle, anterior flexors of the neck, progressing for weeks to months, with or without dysphagia or involvement of respiratory muscles.		
В	Elevation of the serum levels of skeletal muscle enzymes: creatine phosphokinase, aspartate aminotransferase, lactate dehydrogenase, and aldolase. AST		
С	Electromyography characteristic of myopathy (short and small motor units, fibrillations, positive pointy waves, insertional irritability and repetitive high-frequency firing).		
D	Muscle biopsy showing necrosis, phagocytosis, regeneration, perifascicular atrophy, perivascular inflammatory exudate. Muscle biopsy : we don't usually do it. Replaced by MRI		
E	 Typical cutaneous changes: Heliotrope with periorbital edema and violaceous erythema; Gottron's sign: vasculitis in the elbow, metacarpophalangeal, and proximal interphalangeal joints. 		

Criteria for DM			
Definitive	Three criteria (A, B, C or D) + E		
Probable	Two criteria (A, B, C or D) + E		
Possible	One criteria (A, B, C or D) + E		

2275

Updated criteria

CLASSIFICATION CRITERIA FOR ADULT AND JUVENILE IIM

Table 2. The European League Against Rheumatism/American College of Rheumatology (EULAR/ACR) classification criteria for adult and juvenile idiopathic inflammatory myopathics (IIMs)

	Score points			
Variable	Without muscle biopsy	With muscle biopsy	Definition	
Age of onset				
Age of onset of first symptom assumed to be related to the disease ≥18 years and <40 years	1.3	1.5	18 ≤ age (years) at onset of first symptom assumed to be related to the disease <40	
Age of onset of first symptom assumed to be related to the disease ≥40 years	2.1	2.2	Age (years) at onset of first symptom assumed to be related to the disease ≥ 40	
Muscle weakness Objective symmetric weakness, usually progressive, of the proximal upper extremities	0.7	0.7	Weakness of proximal upper extremities as defined by manual muscle testing or other objective strength testing, which is present on both sides and is usually progressive over time	
Objective symmetric weakness, usually progressive, of the proximal lower extremities	0.8	0.5	Weakness of proximal lower extremities as defined by manual muscle testing or other objective strength testing, which is present on both sides and is usually propressive over time.	
Neck flexors are relatively weaker than neck extensors	1.9	1.6	Muscle grades for neck flexors are relatively lower than neck extensors as defined by manual muscle testing or other objective strength testing	
In the legs, proximal muscles are relatively weaker than distal muscles	0.9	1.2	Muscle grades for proximal muscles in the legs are relatively lower than distal muscles in the legs as defined by manual muscle testing or other objective strength treating	
Skin manifestations				
Heliotrope rash	3.1	3.2	Purple, lilac-colored, or erythematous patches over the eyelids or in a periorbital distribution, often associated with periorbital edema	
Gottron's papules	2.1	2.7	Erythematous to violaceous papules over the extensor surfaces of joints, which are sometimes scaly. May occur over the finger joints, elbows, knees, malleoli, and toes	
Gottron's sign	3.3	3.7	Erythematous to violaceous macules over the extensor surfaces of joints, which are not palpable	
Other clinical manifestations Dysphagia or esophageal dysmotility	0.7	0.6	Difficulty in swallowing or objective evidence of abnormal motility of the esophagus	
Laboratory measurements Anti-Jo-1 (anti-histidyl-transfer RNA synthetase) autoantibody present	3.9	3.8	Autoantibody testing in serum performed with standardized and validated test, showing positive result	
Elevated serum levels of creatine kinase (CK)* or lactate dehydrogenase (LDH)* or aspartate aminotransferase (ASAT/AST/SGOT)* or alanine aminotransferase (ALAT/ALT/SGPT)*	1.3	1.4	The most abnormal test values during the disease course (highest absolute level of enzyme) above the relevant upper limit of normal	
Muscle biopsy features—presence of: Endomysial infiltration of mononuclear cells surrounding, but not invading, myofibers		1.7	Muscle biopsy reveals endomysial mononuclear cells abutting the sarcolemma of otherwise healthy, non-necrotic muscle fibers, but there is no clear invasion of the muscle fibers.	
Perimysial and/or perivascular infiltration of mononuclear cells		1.2	Mononuclear cells are located in the perimysium and/or located around blood vessels (in either perimysial or endomysial vessels)	
Perifascicular atrophy		1.9	Muscle biopsy reveals several rows of muscle fibers, which are smaller in the perifascicular region than	
Rimmed vacuoles		3.1	Rimmed vacuoles are bluish by hematoxylin and eosin staining and reddish by modified Gomori trichrome stain	

Don't bother yourself w/ this criteria ; pt w/ typical skin manifestation of gottron's papule or heliotrope is in favor of dermatomyositis

- Patients with pathognomonic skin rashes (heliotrope rash, Gottron's papules, and/or Gottron's sign) of JDM or DM are accurately classified with the EULAR/ACR classification criteria without including muscle biopsy data.
- For patients without these skin manifestations, muscle biopsy is recommended.
- For DM patients without muscle involvement, a skin biopsy is recommended.
- The EULAR/ACR classification criteria provide a score and a corresponding probability of having IIM.
 - A probable IIM:
 - For a total score of ≥5.5 and ≤5.7) for the criteria not including muscle biopsy data, and a score ≥6.7 and ≤7.6 when including muscle biopsies.
 - Definite IIM :
 - For a total aggregate <u>score of 7.5 or more</u> without muscle biopsy and 8.7 with muscle biopsy.



Figure 2. Classification tree for subgroups of idiopathic inflammatory myopathies (IIMs). A patient must first meet the European League Against Rheumatism/American College of Rheumatology (EULAR/ACR) classification criteria for IIM (probability of IIM ≥55%). The patient can then be subclassified using the classification tree. The subgroup of polymyositis (PM) patients includes patients with immune-mediated necrotizing myopathy (IMNM). For inclusion body myositis (IBM) classification, one of the following is required for classification: finger flexor weakness and response to treatment: not improved (+), or muscle biopsy: fimmed vacuoles (++). +++= Juvenile myositis other than juvenile dermatomyositis (JDM) was developed based on expert opinion. IMNM and hypomyopathic dermatomyositis were too few to allow subclassification. ADM = amyopathic dermatomyositis; DM = dermatomyositis.

Juvenile Dermatomyositis

Clinical Presentations (&Notes):



F: calcinosis of the skin . hard material or they ooze calcium like pus Kids who are diagnosed late or treated late are prone to have it

Calcification of subcutaneous can cause disfiguring oozing



Gower's sign : proximal muscle weakness (can't stand w/o hand/chair support)



Nail bed changes : capillary loop changes a part of Vasculitis (hemorrhage due to the inflammation of the vessels and the area w/o blood vessels is called drop out area)



Heliotrope rash: pathognomic . Part of vasculitis . (ask the child to close his eyes)



Shawl sign : skin involvement in exposed area (more lung involvement?)



Gottron's papule: Pathognomic



Malar rash (note: it doesn't spare the nasolabial fold) Ddx of malar rash : lupus or JDM

Juvenile Dermatomyositis

Investigations:

- Muscle enzymes—including creatinine phosphokinase (CPK), LDH, AST (SGOT), ALT (SGPT), adolase (if available). Elevated
- Full blood count and blood film.
- ESR and CRP.
- Myositis-specific and myositis-associated antibodies. Helpful to know prognosis -anti-MDA5 bad prognosis
- Renal function and liver function tests.
- Infection screen (for differential diagnosis).
- Investigations for alternative systemic causes of myopathy including endocrine disorders (especially thyroid function), electrolyte disturbances, vitamin D deficiency.
- Further tests for metabolic/mitochondrial myopathies (especially in the absence of rash/atypical presentation)
- Urine dipstick (with further evaluation if positive for protein)
- Nailfold capillaroscopy
- Echocardiogram and ECG
- Pulmonary function tests (chest X-ray and HRCT if concern)
- MRI of muscles.
- EMG (particularly if suspicion of neuropathy/disorder of neuromuscular junction)
- Muscle biopsy (especially in the absence of rash/atypical presentation)
- MRI brain if neurological involvement suspected.



MRI shows Bright area which is an inflammation of the muscle(hint for proximal muscle weakness) we normally see muscle dark. It involves patchy muscles and bilateral



Treatment:

Combine both

- Steroid. Orally
- Methotrexate (subcutaneous). Once per week , small dose
- Biologics for non responsive cases

Kawasaki Disease

Overview:

- The other name is mucocutaneous lymph node syndrome
- Kawasaki disease mainly affects children of 6 months to 4 or 5 years of age, with a peak at the end of the first year of life.
- It is the commonest cause of acquired heart disease in children (in north america) (in SA is Acute Rheumatic Fever):

Cardiac involvement

Dilation and aneurysm formation, thrombus formation, fibrosis and stenosis, myocardial infarction and it may cause myocarditis and endocarditis

- Systemic inflammatory process (Vasculitis: medium size , mainly coronary arteries) with no known etiology
- Maybe infectious etiology
- More common in children of Japanese and, to a lesser extent, Black-Caribbean ethnicity, than in Caucasians

Diagnosis:

There is no diagnostic test; instead, the diagnosis is made based on clinical findings alone:



renal arteries

Kowasaki Disease

Diagnosis & DDX:

Nonpurulen Conjunctivitis





Hand & Feet Changes

5. Cervical LNs





Differential diagnoses

- Scarlet fever
- **EBV** infection
- Adenovirus infection
- Staphylococcal scalded skin syndrome
- Drug reactions
- Stevens-Johnson syndrome



Young infants may have 'incomplete' symptoms or diseases, in which not all the cardinal features are present:



Figure 3. Evaluation of suspected incomplete Kawasaki disease.

Figure 3. Evaluation of suspected incomplete Kawasaki disease. (1) In the absence of a "gold standard" for diagnosis, this algorithm cannot be evidence based but rather represents the nformed opinion of the expert committee. Consultation with an expert should be sought any time assistance is needed. (2) Clinical findings of Kawasaki disease are listed in Table 3. Characteristics suggesting that another diagnosis should be consid-ared include exudative conjunctivitis, exudative pharyngitis, ulcerative intraoral lesions, bullous or vesicular rash, generalized adenopathy, or splenomegaly. (3) Infants sé months of age are the most likely to develop prolonged fever without other clinical criteria for Kawasaki disease; these infants are at particularly high risk of developing coronary artery abnormalities. (4) Echocar-diography is considered positive for purposes of this algorithm if any of 3 conditions are met Z. Score of left anterior descending coronary artery or right coronary artery 2.5, coronary artery aneruyms in observed; or ≥3 other suggestive features exist, ncluding decreased left ventricular function, mitral regurgitation, pericardial effusion, or Z scores in left anterior descending coronary artery or right coronary artery of 2 to 2.5, (5) If the echocardiogram is positive, treatment should be given within 10 days of fever onset or after the tenth day of fever in the presence of clinical and laboratory signs (Creactive protein (CRP), eryth-ocyte sedimentation rate [ESR]) of ongoing inflammation. (6) Typical peeling begins under the nail beds of fingers and toes. ALT ndicates alanine transaminase; and WBC, white blood cells.

For incomplete symptoms, there should remain a high clinical suspicion, particularly for children less than 6 months of age with prolonged fever and these children are more likely to develop coronary artery aneurysms which affected children within the first 6 weeks. It should be treated as complete KD



Investigations:

- Affected children have high inflammatory markers (C-reactive protein, erythrocyte sedimentation rate, white cell count), with a platelet count that rises typically in the second week of the illness.
- CBC: Neutropenia, leukocytosis (50%) and nonspecific anemia .
- Elevated liver transaminases (40%), low serum albumin level
- Sterile pyuria (33%), aseptic meningitis (up to 50%) •
- Echocardiography should be performed when the diagnosis is first suspected, and at 4–6 weeks to identify coronary artery aneurysms; and it may show a pericardial effusion, myocardial disease (poor contractility), endocardial disease (valve regurgitation), or coronary disease with aneurysm formation, which can be giant (>/= 10 or >8 mm in diameter).
 - If the coronary arteries are abnormal, angiography or magnetic resonance 0 imaging (MRI) will be required.

Kawasaki Disease

Management:

RISK SCORES FOR CORONARY ANEURYSM

- 1. WBC > 12 000
- 2. Platelet < 350 000
- 3. CRP > 3+
- 4. Hct < 3.5
- 5. Albumin < 3.5
- 6. Age </= 12 months
- 7. Male sex



Figure 18.22 Kawasaki disease. Angiogram showing coronary artery aneurysm.

Treatment:

- <u>Intravenous immunoglobulin</u> (IVIG), ideally given within the first 10 days, to lower the risk of coronary artery aneurysms. From 25% to less than 5%
- Aspirin to reduce the risk of thrombosis. due to dilation of the coronary even if there is no dilation start aspirin then re-evaluate after 6 wks with another echo If normal → stop aspirin "coronary changes might develop after this period", <u>decrease</u> aspirin once afebrile
- Children with coronary artery aneurysms require long- term low-dose aspirin and lifelong follow-up.
- Give another anticoagulant if giant aneurysm of CA
- For resistant Kawasaki disease which presents with fever persists or recurs despite initial treatment: give a second dose of:
 - intravenous immunoglobulin or,
 - \circ corticosteroids or,
 - \circ infliximab (a monoclonal antibody against tumour necrosis factor- α)





Juvenile Idiopathic Arthritis (JIA)

- Long term, with uncontrolled disease activity, there may be bone expansion from overgrowth, which in the knee may cause **leg lengthening** or **valgus deformity**; in the hands, discrepancy in digit length; and in the wrist, **advancement of bone age**.
- Proteinuria + renal failure = amyloidosis
- However, untreated anterior uveitis is associated with a high risk of developing glaucoma, cataracts, and optic nerve damage.
- **Osteoporosis** is one of the complications and it is multifactorial: diet, reduced weight bearing, systemic corticosteroids and delayed menarche
- Joint injection (steroids) >> first line of treatment for oligoarticular JIA
- STEROIDS injections are used as bridging agent in polyarticular JIA when starting methotrexate

Subtype, typical age of onset and sex ratio (F:M)	Articular pattern	Extra-articular features	Laboratory abnormalities
Oligoarthritis (persistent) (49%) 1–6 years; F:M, 5:1	1-4 (max) joints involved Knee, ankle or wrist	Chronic anterior uveitis – 20% Leg length discrepancy Prognosis: excellent	ANA+/-
Oligoarthritis (extended) (8%) 1–6 years; F:M, 5:1	>4 joints involved after first 6 months. Asymmetrical distribution of large and small joints	Chronic anterior uveitis – 20% Asymmetrical growth Prognosis: moderate	ANA+/-
Polyarthritis (RF negative) (16%) 1–6 years; F:M, 5:1	Symmetrical large and small joint arthritis, often marked finger involvement Cervical spine and temporomandibular joint may be involved	Low-grade fever Chronic anterior uveitis – 5% Late reduction of growth Prognosis: moderate	
Polyarthritis (RF positive) (3%) 10–16 years; F:M, 5:1	Symmetrical large and small joint arthritis, often marked finger involvement	Rheumatoid nodules – 10% Similar to adult rheumatoid arthritis Prognosis: poor	RF+ (long term)
Systemic arthritis (9%) 1–10 years; M:F, 1:1	Oligoarthritis or polyarthritis. May have aches and pains in joints and muscles (arthralgia/myalgia) but initially no arthritis	Acute illness, malaise, high daily fever initially, with salmon-pink macular rash, lymphadenopathy, hepatosplenomegaly, serositis Prognosis: variable to poor	Anaemia, raisec neutrophils and platelets, high acute-phase reactants
Psoriatic arthritis (7%) 1–16 years; M:F 1:1	Usually asymmetrical distribution of large and small joints, dactylitis	Psoriasis, nail pitting or dystrophy Chronic anterior uveitis – 20% Prognosis: moderate	
Enthesitis-related arthritis (7%) 6–16 years; M:F, 1:4	Lower limb, large joint arthritis initially Mild lumbar spine or sacroiliac involvement later	Enthesitis Occasional acute uveitis Prognosis moderate	HLAB27+

Fig. 28.18 Classification and clinical features of juvenile idiopathic arthritis (JIA). (ANF: Anti-Nuclear Factor; RF: Rheumatoid Factor. Enthesitis – localized inflammation at insertion of tendons or ligaments into bone, often in feet.)

Prolonged fever

 Most childhood infections are acute and resolve in a few days. If not, the child needs to be reassessed for prolonged fever is also required for prompt recognition of Kawasaki disease. Causes:

	Infective		Non-infective
1. 2. 3. 4. 5. 6. 7. 8.	Localized infection: e.g. osteomyelitis. Bacterial infections: e.g. typhoid, Bartonella henselae (cat scratch disease), Brucella species. Deep abscesses: e.g. intra-abdominal retroperitoneal, pelvic. Infective endocarditis. Tuberculosis. Non-tuberculous mycobacterial infections: e.g. Mycobacterium avium complex. Viral infections: e.g. Epstein–Barr virus, cytomegalovirus, HIV (human immunodeficiency virus).	1. 2. 3. 4. 5. 6. 7. 8. 9. 10.	Systemic onset juvenile idiopathic arthritis. Systemic lupus erythematosus. Vasculitis (including Kawasaki disease). Inflammatory bowel disease (Crohn disease and ulcerative colitis). Sarcoidosis. Malignancy: e.g. leukaemia, lymphoma, neuroblastoma, Ewing sarcoma. Macrophage activation syndromes: e.g. haemophagocytic lymphohistiocytosis. Auto-inflammatory disorders: e.g. familial Mediterranean fever (FMF).
9.	Parasitic infections: e.g. malaria, toxocariasis, Entamoeba histolytica.	11. 12.	Fabricated or induced illness (including Munchausen syndrome by proxy).





JUVENILE IDIOPATHIC ARTHRITIS



DIAGNOSIS

- Arthritis in > 1 joint for > 6 weeks 1.
- 2. < 16 years old
- 3. Exclusion of other disease that may cause arthritis

Arthritis is joint pain, stiffness, decreased range of motion, swelling



CLINICAL PRESENTATION						
TYPE	TYPICAL AGE	AFFECTED JOINTS	JOINT PATTERN	EXTRA-ARTICULAR FEATURES		
Oligoarthritis	< 6y	1-4	Asymmetric Large joints	Asymptomatic uveitis		
RF- Polyarthritis	6-7y	<u>≥</u> 5	Symmetric Any sized joints	Asymptomatic uveitis		
RF+ Polyarthritis	9-12y	≥ 5	Symmetric Any sized joints	Rheumatoid nodules, uveitis		
Systemic Arthritis	2-4y	≥1	Any sized joints	Fever, uveitis, lymphadenopathy, rash, serositis, hepatosplenomegaly		
Psoriatic Arthritis	7-10y	<u>≥</u> 1	Asymmetric/symmetric Small-medium joints	Dactylitis, nail pitting, psoriasis, uveitis		
Enthesitis Related Arthritis	9-12y	N/A	Tendon insertions Lower extremities	Symptomatic uveitis		

INVESTIGATIONS

Diagnosis of JIA is based on clinical findings, investigations are used to rule out other conditions and may help classify type.

- CBC .
- ESR/CRP .

XR, U/S, MRI, CT

- RF, ANA
- Children presenting with systemic symptoms should be worked up to
 - rule out infection/malignancy.
- Infection (septic arthritis, osteomyelitis) Malignancy (acute leukemia)
- Growing pains

8

Growth issues

Joint erosion

DDX

Trauma .

.

.

- . Inflammatory Bowel Disease
- Juvenile Dermatomyositis .
- Systemic Lupus Erythematous .
- Vasculitis
- MANAGEMENT PHARMACOLOGIC NON-PHARMACOLOGIC NSAIDS (ibuprofen, naproxen) Regular physical Intra-articular steroids activity Patient education Systemic steroids (short course) **Disease Modifying Anti-**PT/OT Rheumatic Drugs (methotrexate) Psychotherapy Biologics Nutrition .

*Management is based on type of JIA

COMPLICATIONS

- Osteoarthritis
- Osteoporosis Macrophage activation
 - . Functional Psychological .
 - syndrome

Referral to ophthalmology for

regular screening. Untreated uveitis can result in blindness!

Published January 2022 Alicia Synette (Medical Student, Memorial University), Dr. Todd Lambert (Pediatrician, Memorial University) for www.pedscases.com